Journal article
Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population
H Song, E Dicks, SJ Ramus, JP Tyrer, MP Intermaggio, J Hayward, CK Edlund, D Conti, P Harrington, L Fraser, S Philpott, C Anderson, A Rosenthal, A Gentry-Maharaj, DD Bowtell, K Alsop, MS Cicek, JM Cunningham, BL Fridley, J Alsop Show all
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
Purpose: The aim of this study was to estimate the contribution of deleterious mutations in the RAD51B, RAD51C, and RAD51D genes to invasive epithelial ovarian cancer (EOC) in the population and in a screening trial of individuals at high risk of ovarian cancer. Patients and Methods: The coding sequence and splice site boundaries of the three RAD51 genes were sequenced and analyzed in germline DNA from a case-control study of 3,429 patients with invasive EOC and 2,772 controls as well as in 2,000 unaffected women who were BRCA1/BRCA2 negative from the United Kingdom Familial Ovarian Cancer Screening Study (UK-FOCSS) after quality-control analysis. Results: In the case-control study, we ident..
View full abstractGrants
Awarded by Department of Health and Social Care
Funding Acknowledgements
Supported by the Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Australia; the Cancer Foundation of Western Australia; Cancer Research UK (Grants No. C315/A2621, C490/A10119, C490/A10124, C490/A16561, C490/A6187, C1005/A12677, C1005/A6383, and C1005/A7749); the Danish Cancer Society (Grant No. 94 222 52); the Eve Appeal (the Oak Foundation); the Fred C. and Katherine B. Andersen Foundation; the Mermaid I project; the National Institutes of Health (Grants No. P30CA15083, P30CA016056, P50CA136393, R01CA122443, R01CA178535, R01CA61107, R01CA152990, and R01CA086381); the National Health and Medical Research Council of Australia (Grants No. ID400413 and ID400281); the Pomeranian Medical University; Queensland Cancer Fund; Roswell Park Cancer Institute Alliance Foundation; the United Kingdom Department of Health; the United Kingdom National Institute for Health Research Biomedical Research Centres at the University of Cambridge and at the University College London Hospitals; and the US Army Medical Research and Material Command (Grant No. DAMD17-01-1-0729). J.H. was funded by a United Kingdom Medical Research Council CASE industrial partnership PhD studentship. I. J. J. holds an NIHR senior investigator award.